The STAT report on GSK's bepirovirsen highlights functional cure rates of 19-20% in two Phase 3 RCTs, dwarfing the 1-3% seen with nucleoside analogues. These double-blind, placebo-controlled trials represent a methodological advance over prior observational cohorts, though exact sample sizes and full safety datasets remain undisclosed in the initial release. What routine coverage overlooks is bepirovirsen's mechanism as an antisense oligonucleotide that degrades HBV RNA and indirectly targets covalently closed circular DNA reservoirs, unlike nucleos(t)ide therapies that merely suppress replication. A 2022 NEJM Phase 2 study (Yuen et al., n=457) already foreshadowed dose-dependent HBsAg declines, yet overlooked long-term durability beyond 24 weeks. WHO 2024 estimates of 254 million chronic cases and 1.1 million annual deaths underscore the gap; combining bepirovirsen with capsid inhibitors or therapeutic vaccines could push rates above 30%, as hinted in emerging combination modeling. Conflicts of interest are notable: GSK funded all trials, with investigators reporting consulting fees. Observational real-world data from Taiwan's REVEAL cohort show functional cure rarity without novel agents, reinforcing why these RCTs matter despite limited diversity in Asian-predominant enrollment.